---
document_datetime: 2025-12-02 05:11:18
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/vidprevtyn-beta.html
document_name: vidprevtyn-beta.html
version: success
processing_time: 0.1123015
conversion_datetime: 2025-12-26 17:43:52.959659
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# VidPrevtyn Beta

[RSS](/en/individual-human-medicine.xml/67644)

##### Withdrawn

This medicine's authorisation has been withdrawn

COVID-19 Vaccine (recombinant, adjuvanted) Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Safety updates](#safety-updates)
- [News on VidPrevtyn Beta](#news-on)
- [More information on VidPrevtyn Beta](#more-information-on-vidprevtyn-beta-66321)
- [More information on VidPrevtyn Beta](#related-medicines)

- Rolling review
- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

The marketing authorisation for Vidprevtyn Beta has been withdrawn at the request of the marketing-authorisation holder.

VidPrevtyn Beta : EPAR - Medicine overview

Reference Number: EMA/872778/2022

English (EN) (236.94 KB - PDF)

**First published:** 11/11/2022

**Last updated:** 20/03/2024

[View](/en/documents/overview/vidprevtyn-beta-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-232)

български (BG) (332.14 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/bg/documents/overview/vidprevtyn-beta-epar-medicine-overview_bg.pdf)

español (ES) (247.63 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/es/documents/overview/vidprevtyn-beta-epar-medicine-overview_es.pdf)

čeština (CS) (301.37 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/cs/documents/overview/vidprevtyn-beta-epar-medicine-overview_cs.pdf)

dansk (DA) (241.25 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/da/documents/overview/vidprevtyn-beta-epar-medicine-overview_da.pdf)

Deutsch (DE) (260.4 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/de/documents/overview/vidprevtyn-beta-epar-medicine-overview_de.pdf)

eesti keel (ET) (220.24 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/et/documents/overview/vidprevtyn-beta-epar-medicine-overview_et.pdf)

ελληνικά (EL) (340.19 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/el/documents/overview/vidprevtyn-beta-epar-medicine-overview_el.pdf)

français (FR) (253.61 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/fr/documents/overview/vidprevtyn-beta-epar-medicine-overview_fr.pdf)

hrvatski (HR) (287.1 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/hr/documents/overview/vidprevtyn-beta-epar-medicine-overview_hr.pdf)

italiano (IT) (243.5 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/it/documents/overview/vidprevtyn-beta-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (300.67 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/lv/documents/overview/vidprevtyn-beta-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (296.7 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/lt/documents/overview/vidprevtyn-beta-epar-medicine-overview_lt.pdf)

magyar (HU) (278.93 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/hu/documents/overview/vidprevtyn-beta-epar-medicine-overview_hu.pdf)

Malti (MT) (317.29 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/mt/documents/overview/vidprevtyn-beta-epar-medicine-overview_mt.pdf)

Nederlands (NL) (258.51 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/nl/documents/overview/vidprevtyn-beta-epar-medicine-overview_nl.pdf)

polski (PL) (314.64 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/pl/documents/overview/vidprevtyn-beta-epar-medicine-overview_pl.pdf)

português (PT) (248.32 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/pt/documents/overview/vidprevtyn-beta-epar-medicine-overview_pt.pdf)

română (RO) (308.86 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/ro/documents/overview/vidprevtyn-beta-epar-medicine-overview_ro.pdf)

slovenčina (SK) (309.79 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/sk/documents/overview/vidprevtyn-beta-epar-medicine-overview_sk.pdf)

slovenščina (SL) (285.56 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/sl/documents/overview/vidprevtyn-beta-epar-medicine-overview_sl.pdf)

Suomi (FI) (242.32 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/fi/documents/overview/vidprevtyn-beta-epar-medicine-overview_fi.pdf)

svenska (SV) (238.95 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/sv/documents/overview/vidprevtyn-beta-epar-medicine-overview_sv.pdf)

VidPrevtyn Beta : EPAR - Risk-management-plan

English (EN) (8.41 MB - PDF)

**First published:** 11/11/2022

**Last updated:** 20/03/2024

[View](/en/documents/rmp/vidprevtyn-beta-epar-risk-management-plan_en.pdf)

## Product information

VidPrevtyn Beta : EPAR - Product information

English (EN) (1.33 MB - PDF)

**First published:** 10/11/2022

**Last updated:** 20/03/2024

[View](/en/documents/product-information/vidprevtyn-beta-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-297)

български (BG) (1.71 MB - PDF)

**First published:**

10/11/2022

**Last updated:**

20/03/2024

[View](/bg/documents/product-information/vidprevtyn-beta-epar-product-information_bg.pdf)

español (ES) (1.35 MB - PDF)

**First published:**

10/11/2022

**Last updated:**

20/03/2024

[View](/es/documents/product-information/vidprevtyn-beta-epar-product-information_es.pdf)

čeština (CS) (2.01 MB - PDF)

**First published:**

10/11/2022

**Last updated:**

20/03/2024

[View](/cs/documents/product-information/vidprevtyn-beta-epar-product-information_cs.pdf)

dansk (DA) (1.33 MB - PDF)

**First published:**

10/11/2022

**Last updated:**

20/03/2024

[View](/da/documents/product-information/vidprevtyn-beta-epar-product-information_da.pdf)

Deutsch (DE) (763.5 KB - PDF)

**First published:**

10/11/2022

**Last updated:**

20/03/2024

[View](/de/documents/product-information/vidprevtyn-beta-epar-product-information_de.pdf)

eesti keel (ET) (1.1 MB - PDF)

**First published:**

10/11/2022

**Last updated:**

20/03/2024

[View](/et/documents/product-information/vidprevtyn-beta-epar-product-information_et.pdf)

ελληνικά (EL) (2.41 MB - PDF)

**First published:**

10/11/2022

**Last updated:**

20/03/2024

[View](/el/documents/product-information/vidprevtyn-beta-epar-product-information_el.pdf)

français (FR) (1.94 MB - PDF)

**First published:**

10/11/2022

**Last updated:**

20/03/2024

[View](/fr/documents/product-information/vidprevtyn-beta-epar-product-information_fr.pdf)

hrvatski (HR) (1.34 MB - PDF)

**First published:**

10/11/2022

**Last updated:**

20/03/2024

[View](/hr/documents/product-information/vidprevtyn-beta-epar-product-information_hr.pdf)

íslenska (IS) (1.62 MB - PDF)

**First published:**

10/11/2022

**Last updated:**

20/03/2024

[View](/is/documents/product-information/vidprevtyn-beta-epar-product-information_is.pdf)

italiano (IT) (1.4 MB - PDF)

**First published:**

10/11/2022

**Last updated:**

20/03/2024

[View](/it/documents/product-information/vidprevtyn-beta-epar-product-information_it.pdf)

latviešu valoda (LV) (1.41 MB - PDF)

**First published:**

10/11/2022

**Last updated:**

20/03/2024

[View](/lv/documents/product-information/vidprevtyn-beta-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.36 MB - PDF)

**First published:**

10/11/2022

**Last updated:**

20/03/2024

[View](/lt/documents/product-information/vidprevtyn-beta-epar-product-information_lt.pdf)

magyar (HU) (1.88 MB - PDF)

**First published:**

10/11/2022

**Last updated:**

20/03/2024

[View](/hu/documents/product-information/vidprevtyn-beta-epar-product-information_hu.pdf)

Malti (MT) (1.75 MB - PDF)

**First published:**

10/11/2022

**Last updated:**

20/03/2024

[View](/mt/documents/product-information/vidprevtyn-beta-epar-product-information_mt.pdf)

Nederlands (NL) (997.84 KB - PDF)

**First published:**

10/11/2022

**Last updated:**

20/03/2024

[View](/nl/documents/product-information/vidprevtyn-beta-epar-product-information_nl.pdf)

norsk (NO) (1.31 MB - PDF)

**First published:**

10/11/2022

**Last updated:**

20/03/2024

[View](/no/documents/product-information/vidprevtyn-beta-epar-product-information_no.pdf)

polski (PL) (1.75 MB - PDF)

**First published:**

10/11/2022

**Last updated:**

20/03/2024

[View](/pl/documents/product-information/vidprevtyn-beta-epar-product-information_pl.pdf)

português (PT) (1.46 MB - PDF)

**First published:**

10/11/2022

**Last updated:**

20/03/2024

[View](/pt/documents/product-information/vidprevtyn-beta-epar-product-information_pt.pdf)

română (RO) (1.61 MB - PDF)

**First published:**

10/11/2022

**Last updated:**

20/03/2024

[View](/ro/documents/product-information/vidprevtyn-beta-epar-product-information_ro.pdf)

slovenčina (SK) (2.15 MB - PDF)

**First published:**

10/11/2022

**Last updated:**

20/03/2024

[View](/sk/documents/product-information/vidprevtyn-beta-epar-product-information_sk.pdf)

slovenščina (SL) (1.69 MB - PDF)

**First published:**

10/11/2022

**Last updated:**

20/03/2024

[View](/sl/documents/product-information/vidprevtyn-beta-epar-product-information_sl.pdf)

Suomi (FI) (1.53 MB - PDF)

**First published:**

10/11/2022

**Last updated:**

20/03/2024

[View](/fi/documents/product-information/vidprevtyn-beta-epar-product-information_fi.pdf)

svenska (SV) (1.52 MB - PDF)

**First published:**

10/11/2022

**Last updated:**

20/03/2024

[View](/sv/documents/product-information/vidprevtyn-beta-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0007/G 11/03/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

VidPrevtyn Beta : EPAR - All authorised presentations

English (EN) (90.38 KB - PDF)

**First published:** 11/11/2022

**Last updated:** 20/03/2024

[View](/en/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-144)

български (BG) (118.8 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/bg/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_bg.pdf)

español (ES) (94.34 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/es/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_es.pdf)

čeština (CS) (113.37 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/cs/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (107.73 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/da/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (96.35 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/de/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (61.27 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/et/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (116.16 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/el/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_el.pdf)

français (FR) (107.82 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/fr/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (87.38 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/hr/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (102.35 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/is/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_is.pdf)

italiano (IT) (90.96 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/it/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (89.83 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/lv/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (83.47 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/lt/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (85.1 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/hu/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (171.03 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/mt/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (88.94 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/nl/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (110.72 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/no/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_no.pdf)

polski (PL) (125.12 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/pl/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_pl.pdf)

português (PT) (176.9 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/pt/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_pt.pdf)

română (RO) (98.92 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/ro/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (88.21 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/sk/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (139.29 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/sl/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (100.61 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/fi/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (107.86 KB - PDF)

**First published:**

11/11/2022

**Last updated:**

20/03/2024

[View](/sv/documents/all-authorised-presentations/vidprevtyn-beta-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine VidPrevtyn Beta Active substance SARS-CoV-2 prefusion Spike delta TM protein, recombinant (B.1.351 strain) International non-proprietary name (INN) or common name COVID-19 Vaccine (recombinant, adjuvanted) Therapeutic area (MeSH) COVID-19 virus infection Anatomical therapeutic chemical (ATC) code J07BN04

### Pharmacotherapeutic group

Vaccines

### Therapeutic indication

VidPrevtyn Beta is indicated as a booster for active immunisation to prevent COVID-19 in adults who have previously received an mRNA or adenoviral vector COVID-19 vaccine (see sections 4.2 and 5.1 in product information document).

The use of this vaccine should be in accordance with official recommendations.

## Authorisation details

EMA product number EMEA/H/C/005754 Marketing authorisation holder

Sanofi Pasteur

14 Espace Henry Vallée

Opinion adopted 10/11/2022 Marketing authorisation issued 10/11/2022 Withdrawal of marketing authorisation 18/03/2024 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

VidPrevtyn Beta : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (229.51 KB - PDF)

**First published:** 08/11/2023

**Last updated:** 20/03/2024

[View](/en/documents/procedural-steps-after/vidprevtyn-beta-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

VidPrevtyn Beta-H-C-PSUSA-00011035-202305 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/67397/2024

English (EN) (171.96 KB - PDF)

**First published:** 13/02/2024

**Last updated:** 20/03/2024

[View](/en/documents/scientific-conclusion/vidprevtyn-beta-h-c-psusa-00011035-202305-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations_en.pdf)

## Initial marketing authorisation documents

VidPrevtyn Beta : EPAR - Public assessment report

Adopted

Reference Number: EMA/893684/2022

English (EN) (12.98 MB - PDF)

**First published:** 30/11/2022

**Last updated:** 20/03/2024

[View](/en/documents/assessment-report/vidprevtyn-beta-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for VidPrevtyn Beta

Adopted

Reference Number: EMA/867425/2022

English (EN) (290.09 KB - PDF)

**First published:** 10/11/2022

**Last updated:** 20/03/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-vidprevtyn-beta_en.pdf)

#### Safety updates

COVID-19 vaccines - Safety update: 8 December 2022

Adopted

English (EN) (239.73 KB - PDF)

**First published:** 08/12/2022

**Last updated:** 09/08/2024

[View](/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-8-december-2022_en.pdf)

VidPrevtyn Beta: Periodic safety update report assessment 10 May 2023 to 9 November 2023

Adopted

English (EN) (7.97 MB - PDF)

**First published:** 30/07/2024

[View](/en/documents/covid-19-vaccine-safety-update/vidprevtyn-beta-periodic-safety-update-report-assessment-10-may-2023-9-november-2023_en.pdf)

VidPrevtyn Beta: Periodic safety update report assessment 10 November 2022 to 9 May 2023

Adopted

English (EN) (13.77 MB - PDF)

**First published:** 20/02/2024

**Last updated:** 20/03/2024

[View](/en/documents/covid-19-vaccine-safety-update/vidprevtyn-beta-periodic-safety-update-report-assessment-10-november-2022-9-may-2023_en.pdf)

#### News on VidPrevtyn Beta

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-november-2022) 11/11/2022

[EMA recommends approval of VidPrevtyn Beta as a COVID 19 booster vaccine](/en/news/ema-recommends-approval-vidprevtyn-beta-covid-19-booster-vaccine) 10/11/2022

#### More information on VidPrevtyn Beta

Public statement on VidPrevtyn Beta: Withdrawal of the marketing authorisation in the European Union

Reference Number: EMA/585020/2023

English (EN) (122.74 KB - PDF)

**First published:** 20/03/2024

[View](/en/documents/public-statement/public-statement-vidprevtyn-beta-withdrawal-marketing-authorisation-european-union_en.pdf)

#### More information on VidPrevtyn Beta

- [EMEA-002915-PIP01-20-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002915-pip01-20-m03)

**This page was last updated on** 30/07/2024

## Share this page

[Back to top](#main-content)